Published in Int J Pharm on May 20, 2014
Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism. Biomaterials (2015) 0.83
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf B Biointerfaces (2016) 0.77
Nanoparticle mediated chemotherapy of hormone refractory prostate cancer with a novel combi-molecule. Am J Transl Res (2015) 0.75
Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) (2016) 0.75
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
Nanoparticle delivery of cancer drugs. Annu Rev Med (2011) 3.75
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Solubilizing excipients in oral and injectable formulations. Pharm Res (2004) 3.08
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest (1997) 2.96
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci (2000) 2.81
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res (2005) 2.21
Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A (1994) 2.17
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets (2003) 1.75
Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol (2010) 1.61
The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta (2001) 1.54
Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton (2003) 1.50
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer (2012) 1.38
Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol (2010) 1.35
Docetaxel-related side effects and their management. Eur J Oncol Nurs (2009) 1.29
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J Control Release (2012) 1.20
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone (2008) 1.18
Microvascular architecture of experimental colon tumors in the rat. Cancer Res (1990) 1.16
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev (2008) 1.11
Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol (2011) 1.11
Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin (2008) 1.07
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res (2000) 1.01
A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med (2011) 1.00
Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol (2002) 1.00
Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles. Biomacromolecules (2007) 0.97
Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules (2010) 0.95
Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells. Bioconjug Chem (2011) 0.91
Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer. J Control Release (2013) 0.89
Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine (2012) 0.89
Broadening horizons in medical management of prostate cancer. Acta Oncol (2011) 0.88
TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol (2011) 0.87
Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med (1999) 0.86
Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Release (2006) 0.86
Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst (2009) 0.86
Mouse femoral intramedullary injection model: technique and microCT scan validation. J Biomed Mater Res B Appl Biomater (2008) 0.83
Current development in nanoformulations of docetaxel. Expert Opin Drug Deliv (2012) 0.82
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol (2012) 0.79